The detection of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-sensitizing mutations is important in guiding the treatment of advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.